The secret Israeli sauce in Pfizer s new drug mix timesofisrael.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from timesofisrael.com Daily Mail and Mail on Sunday newspapers.
Sitryx further strengthens leadership team with the appointment of Iain Kilty, Ph.D., as Chief Scientific Officer
April 15, 2021 02:00 ET | Source: Sitryx Therapeutics Sitryx Therapeutics LONDON, UNITED KINGDOM
Sitryx further strengthens leadership team with the appointment of Iain Kilty, Ph.D., as Chief Scientific Officer
Oxford, UK – 15 April 2021 – Sitryx (“the Company”), a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation, today announces the appointment of Iain Kilty, Ph.D., as its Chief Scientific Officer.
Iain will lead the development and execution of the Company’s research strategy and advancement of the Company’s pipeline of disease-modifying therapeutics in immuno-oncology and immuno-inflammation.
A New Frontier to Fight This Hair-Loss Disease
Copy link
Caption
Alopecia areata, an autoimmune disease in which patients lose hair in random patches, impacts 2 percent of people globally, yet there are no FDA-approved treatments. But promising options are emerging.
By Ian Graber-Stiehl
Copy link
WHY YOU SHOULD CARE
Because this disease affects 2 percent of people globally and might be on the verge of its first effective treatment.
By Ian Graber-Stiehl
Alopecia areata, an autoimmune disease in which patients lose hair in random patches, impacts 2 percent of people globally, yet there are no FDA-approved treatments. People with the condition are also more prone to depression.
Hits: 1464
Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active, specific immunotherapies for the treatment of severe, chronic autoimmune diseases, today enters into Research Collaboration and License Agreement for its Imotope™ Technology with Pfizer in Rheumatoid Arthritis
• Imcyse and Pfizer to collaborate to develop Imotope™ candidates to potentially treat Rheumatoid Arthritis
• Pfizer to lead clinical development and commercialization activities
• Imcyse to receive upfront payment in cash and through the purchase of equity in addition to milestone up to $180 million and tiered royalty payments
LIEGE, Belgium I February 03, 2021 I Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, today announced that it has entered into a research collaboration and license agreement with Pfi
Imcyse for a rheumatoid arthritis program, which is based on that company’s Imotope technology.
Pfizer will lead clinical development of the RA program. This is not the first rheumatoid arthritis deal Pfizer and Imcyse have conducted.
In 2018, the companies entered into an agreement to develop an Imotope, which is a specific modified peptide that targets rheumatoid arthritis. The Imcyse Imotope platform represents what the companies believe is a next generation and potentially curative approach to severe autoimmune diseases.
Imotopes are designed to induce cytolytic T cells, which specifically eliminate the aberrant disease pathway while leaving the rest of the immune system unaffected. It is believed that treatment with a specific Imotope has the potential to disrupt the undesirable immune response that drives the process of destruction of the healthy cells.